Loading...

Zomedica Corp.

ZOMAMEX
HealthcareDrug Manufacturers - Specialty & Generic
$0.10
$-0.00(-0.21%)

Zomedica Corp. (ZOM) Stock Overview

Explore Zomedica Corp.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
33.05%
33.05%
Profit Growth
$-0.06
102.93%
EPS Growth
$-0.06
102.30%
Operating Margin
-143.14%
44.10%
ROE
-28.16%
102.93%
Dividend Yield
0.00%
Analyst Recommendations data is not available for ZOMAnalyst Recommendations details for ZOM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

CEO

Mr. Larry C. Heaton II

Employees

144

Headquarters

100 Phoenix Drive, Ann Arbor, MI

Founded

2017

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.